Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

OLUTASIDENIB for Brain neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 24 adverse event reports in the FDA FAERS database where OLUTASIDENIB was used for Brain neoplasm malignant.

Most Reported Side Effects for OLUTASIDENIB

Side Effect Reports % Deaths Hosp.
Off label use 59 28.1% 3 18
Hospitalisation 27 12.9% 3 27
Death 24 11.4% 24 6
Nausea 23 11.0% 0 11
Fatigue 21 10.0% 1 7
Product dose omission issue 19 9.1% 1 6
Product prescribing issue 15 7.1% 0 5
Constipation 14 6.7% 1 7
Transfusion 11 5.2% 1 4
Pneumonia 9 4.3% 2 9
Asthenia 7 3.3% 0 2
Dyspnoea 7 3.3% 0 2
Product use issue 7 3.3% 2 1
Rash 7 3.3% 1 3
Vomiting 7 3.3% 0 2

Other Indications for OLUTASIDENIB

Acute myeloid leukaemia (119) Acute myeloid leukaemia refractory (19) Myelodysplastic syndrome (14) Product used for unknown indication (8) Myelodysplastic syndrome with excess blasts (5)

Other Drugs Used for Brain neoplasm malignant

PROCARBAZINE (2,283) TEMOZOLOMIDE (2,202) BEVACIZUMAB (740) TRAMETINIB DIMETHYL SULFOXIDE (317) LOMUSTINE (291) THALIDOMIDE (195) DABRAFENIB (189) IVOSIDENIB (140) SELINEXOR (136) AVAPRITINIB (122)

Related Pages

OLUTASIDENIB Full Profile All Brain neoplasm malignant Drugs OLUTASIDENIB Demographics OLUTASIDENIB Timeline